In-Hospital Complications and Readmission in Patients with Hemophilia Undergoing Hip or Knee Arthroplasty.


Journal

JB & JS open access
ISSN: 2472-7245
Titre abrégé: JB JS Open Access
Pays: United States
ID NLM: 101726219

Informations de publication

Date de publication:
Historique:
entrez: 30 10 2020
pubmed: 31 10 2020
medline: 31 10 2020
Statut: epublish

Résumé

Individuals with hemophilia undergoing hip or knee arthroplasty are at risk for complications such as bleeding and infection. However, data on hospital length of stay (LOS) and readmission rates compared with nonhemophilic controls are lacking. This study compared the complication rates, LOS, and unplanned 30-day readmission rates between patients with hemophilia and nonhemophilic controls. This retrospective cohort study used the Pennsylvania Health Care Cost Containment Council (PHC4) database from 2007 to 2015 to compare outcomes in patients with hemophilia and nonhemophilic controls undergoing partial and total hip arthroplasty, knee arthroplasty, and revision knee arthroplasty. A total of 118 patients with hemophilia and 3,811 controls were identified. Compared with controls, patients with hemophilia had a higher risk of bleeding complications after hip procedures (38.7% versus 16.1%, p = 0.003), a higher risk of surgical site infection after knee procedures (8.1% versus 1.1%, p < 0.001), longer median LOS after hip (6 versus 3 days, p < 0.001) and knee (5 versus 3 days, p < 0.001) procedures, and higher rates of unplanned 30-day readmission after hip (22.6% versus 4.1%, p < 0.001) and knee (10.3% versus 4.5%, p = 0.018) procedures. The most common reason for unplanned 30-day readmission in patients with hemophilia was bleeding or the patient's underlying coagulopathy (25.1%). Patients with hemophilia undergoing hip or knee arthroplasty had a higher incidence of postoperative bleeding (hip procedures) and surgical site infections (knee procedures), longer LOS, and higher rates of unplanned 30-day readmission compared with nonhemophilic controls. Key limitations of our study include the potential for inaccurate coding, the relatively small number of patients in the hemophilia cohort, and the uneven distribution of procedure type in the hemophilia and control cohorts. Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.

Sections du résumé

BACKGROUND BACKGROUND
Individuals with hemophilia undergoing hip or knee arthroplasty are at risk for complications such as bleeding and infection. However, data on hospital length of stay (LOS) and readmission rates compared with nonhemophilic controls are lacking. This study compared the complication rates, LOS, and unplanned 30-day readmission rates between patients with hemophilia and nonhemophilic controls.
METHODS METHODS
This retrospective cohort study used the Pennsylvania Health Care Cost Containment Council (PHC4) database from 2007 to 2015 to compare outcomes in patients with hemophilia and nonhemophilic controls undergoing partial and total hip arthroplasty, knee arthroplasty, and revision knee arthroplasty.
RESULTS RESULTS
A total of 118 patients with hemophilia and 3,811 controls were identified. Compared with controls, patients with hemophilia had a higher risk of bleeding complications after hip procedures (38.7% versus 16.1%, p = 0.003), a higher risk of surgical site infection after knee procedures (8.1% versus 1.1%, p < 0.001), longer median LOS after hip (6 versus 3 days, p < 0.001) and knee (5 versus 3 days, p < 0.001) procedures, and higher rates of unplanned 30-day readmission after hip (22.6% versus 4.1%, p < 0.001) and knee (10.3% versus 4.5%, p = 0.018) procedures. The most common reason for unplanned 30-day readmission in patients with hemophilia was bleeding or the patient's underlying coagulopathy (25.1%).
CONCLUSIONS CONCLUSIONS
Patients with hemophilia undergoing hip or knee arthroplasty had a higher incidence of postoperative bleeding (hip procedures) and surgical site infections (knee procedures), longer LOS, and higher rates of unplanned 30-day readmission compared with nonhemophilic controls. Key limitations of our study include the potential for inaccurate coding, the relatively small number of patients in the hemophilia cohort, and the uneven distribution of procedure type in the hemophilia and control cohorts.
LEVEL OF EVIDENCE METHODS
Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.

Identifiants

pubmed: 33123670
doi: 10.2106/JBJS.OA.19.00085
pii: JBJSOA-D-19-00085
pmc: PMC7418913
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e0085

Informations de copyright

Copyright © 2020 The Authors. Published by The Journal of Bone and Joint Surgery, Incorporated. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure: The authors indicated that no external funding was received for any aspect of this work. On the Disclosure of Potential Conflicts of Interest forms, which are provided with the online version of the article, one or more of the authors checked “yes” to indicate that the author had a relevant financial relationship in the biomedical arena outside the submitted work (http://links.lww.com/JBJSOA/A173).

Références

Thromb Haemost. 2016 Jul 4;116(1):42-9
pubmed: 27009484
J Thromb Haemost. 2010 Sep;8(9):1895-902
pubmed: 20586922
Blood Coagul Fibrinolysis. 2014 Jun;25(4):300-2
pubmed: 24781681
J Orthop Surg (Hong Kong). 2019 Jan-Apr;27(1):2309499019834337
pubmed: 30852987
Haemophilia. 2011 Sep;17(5):e831-2
pubmed: 21507150
Clin Appl Thromb Hemost. 2016 Mar;22(2):161-5
pubmed: 25008348
Br J Haematol. 2009 Apr;145(2):227-34
pubmed: 19236610
Chest. 2012 Feb;141(2 Suppl):e278S-e325S
pubmed: 22315265
Thromb Res. 2015 Jan;135(1):109-13
pubmed: 25434629
Haemophilia. 2011 Nov;17(6):910-9
pubmed: 21342367
Orthop Surg. 2019 Apr;11(2):236-240
pubmed: 30932356
J Orthop. 2018 May 07;15(2):558-562
pubmed: 29881193
Haemophilia. 2009 Nov;15(6):1337-8
pubmed: 19702632
J Arthroplasty. 2019 Oct;34(10):2329-2336.e1
pubmed: 31337553
Haemophilia. 2016 Jul;22(4):e275-85
pubmed: 27444973

Auteurs

Thita Chiasakul (T)

Division of Hematology, Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.

Tyler W Buckner (TW)

Hemophilia and Thrombosis Center, University of Colorado School of Medicine, Aurora, Colorado.

Mingyang Li (M)

Departments of Biostatistics, Epidemiology and Informatics (M.L. and P.A.G.), Medicine (R.V. and A.C.), and Pathology and Laboratory Medicine (A.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Rolando Vega (R)

Departments of Biostatistics, Epidemiology and Informatics (M.L. and P.A.G.), Medicine (R.V. and A.C.), and Pathology and Laboratory Medicine (A.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Phyllis A Gimotty (PA)

Departments of Biostatistics, Epidemiology and Informatics (M.L. and P.A.G.), Medicine (R.V. and A.C.), and Pathology and Laboratory Medicine (A.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Adam Cuker (A)

Departments of Biostatistics, Epidemiology and Informatics (M.L. and P.A.G.), Medicine (R.V. and A.C.), and Pathology and Laboratory Medicine (A.C.), Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Classifications MeSH